Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPANOVA and OMACOR pharmacokinetics in type 2 diabetes with pancreatic exocrine insufficiency
2014-003511-11Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2014
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eicosapentaenoic acid + docosahexaenoic acid and omega-3-acid triglycerides in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by AstraZeneca. Primary endpoints: Plasma triglyceride levels, Faecal elastase-1 concentration and 1 more. Started Dec 2014; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acidomega-3-acid triglycerides
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-003511-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003511-11.